Skin Channel
Topics
Medications
Quicklinks
Related Channels

Denileukin Diftitox Drug Information

A healthcare provider may prescribe denileukin diftitox (Ontak®) for the treatment of cutaneous T-cell lymphoma when other chemotherapy treatments have failed. It is administered by a healthcare provider in a healthcare setting. Each dose is given as an intravenous (IV) injection for five days in a row, once every three weeks.
 
This drug is specifically approved for treating cancer that has a certain protein on the surface of the cells. After binding to these proteins, denileukin diftitox releases diphtheria toxin, which causes the cancer cells to die.
 
Although it may be an effective medication, not everyone can use this drug. Information on denileukin diftitox should be reviewed with your healthcare provider before starting treatment to help ensure this is the right chemotherapy treatment for you. For instance, you may not be able to use this medicine if you are taking certain medications or have a history of low albumin levels.
 
(Click Denileukin Diftitox for more details on this drug, including information on what your healthcare provider needs to know, potentially dangerous complications that may occur, and why this chemotherapy medicine may not be safe for certain people.)
 

Denileukin Diftitox Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.